ICAD Profile
iCAD, Inc., headquartered in Nashua, New Hampshire, specializes in providing advanced image analysis, workflow solutions, and radiation therapy technologies for the detection and treatment of cancer across the United States. The company operates through two primary segments: Cancer Detection and Cancer Therapy, each focused on pioneering innovations in oncological diagnostics and treatment.
Under its Cancer Detection segment, iCAD offers the PowerLook platform, a robust system that integrates AI-driven algorithm solutions, facilitating seamless communication between imaging acquisition systems and storage/review platforms. Its flagship product, SecondLook, utilizes machine learning to analyze 2D full-field digital mammography images, identifying suspicious masses and calcifications. The company also provides automated density assessment solutions, ensuring consistent and standardized breast density evaluations.
In the realm of cancer therapy, iCAD's offerings include ProFound AI, a deep-learning algorithm designed for detecting malignant soft-tissue densities and calcifications in digital breast tomosynthesis. The ProFound AI Risk tool enhances clinical decision-making by estimating breast cancer risk based on screening mammograms. Additionally, iCAD's magnetic resonance imaging applications aid in the early detection of breast and prostate cancers, further bolstering its comprehensive diagnostic capabilities.
Beyond diagnostics, iCAD manufactures the Xoft Axxent electronic brachytherapy systems, tailored for the treatment of early-stage breast, non-melanoma skin, and gynecological cancers. These systems are utilized across university research hospitals, community healthcare facilities, veterinary clinics, and dermatology practices. The company markets its products through a diverse network of direct sales teams, original equipment manufacturers, distributors, technology partners, and resellers, extending its reach across global markets including Europe, Taiwan, Canada, China, and beyond. With a history dating back to 1984, iCAD continues to innovate in the field of oncology, striving to improve patient outcomes through cutting-edge technologies and strategic partnerships.
|
